Glioblastoma cells follow predictable, rule-based trajectories as they evolve, according to a study published November 3, 2026, in the journal Nature. By mapping over one million individual cells from 12 patients, researchers demonstrated that these tumors are not chaotic, but rather progress through specific, stereotyped states that can be targeted by new therapeutic strategies.
Mapping the architecture of brain tumors
The research team, involving scientists from the Wellcome Sanger Institute, the European Molecular Biology Laboratory (EMBL), the German Cancer Research Center (DKFZ), and the Cancer Research UK Cambridge Institute, utilized single-cell and spatial transcriptomic data to build the GBM-Space atlas. This resource reveals that glioblastoma cells occupy distinct spatial microenvironments based on their developmental stage. The study was supported by a Wellcome Leap grant and emerged from a foundational effort to map glioblastoma biology without relying on prior assumptions.
All 12 tumor samples analyzed in the study came from patients undergoing neurosurgery at Cambridge University Hospitals NHS Foundation Trust. Patients provided pre-operative consent under the Declaration of Helsinki 2000, with ethical approval secured from the Cambridge Local Research Ethics Committee (REC 18/EE/0172).
By integrating the single-cell data with spatial transcriptomic data, we found that there is a meticulous and very specific spatial architecture of cancer cell states,
said Omer Bayraktar, co-senior author of the study at the Wellcome Sanger Institute. We asked – can we go back to the drawing board?
The study indicates that as tumors expand, cells shift into injury-response states that mimic brain tissue repair pathways. In later stages, regions of the tumor deprived of oxygen force cells into severe hypoxic states.
Using AI to identify regulatory drivers
To understand the mechanisms governing this plasticity, the team developed a deep-learning framework called scDORI. This tool allowed researchers to compare how transcriptional regulators and target genes co-vary, uncovering the gene regulatory networks that dictate cell fate. The approach uses single-cell multi-omic data to define and perturb the networks controlling glioblastoma plasticity.
The analysis identified a crucial class of molecular “safeguards”—transcription factors that act as developmental brakes, arresting cells in stable, low-plasticity states and preventing them from shifting into therapy-resistant or invasive phenotypes.
The researchers identified the safeguard factor MYT1L as a key regulator. Conversely, the loss of MYT1L was found to reactivate plasticity and accelerate malignant features.
Implications for clinical treatment
Around 3,200 people are diagnosed with the disease every year in the United Kingdom. Average survival is 12 to 18 months, and only 4 percent of those diagnosed survive five years or more.
For too long, we’ve approached glioblastoma treatment knowing that each patient’s tumour contains a complex mixture of cancer cells, but without a clear understanding of how best to target them all,
said Dr. Richard Mair, a brain surgeon and researcher at the Cancer Research UK Cambridge Institute. This research gives us an opportunity to think differently.
The team suggests that by identifying the specific regulatory sequences that drive these transitions, future treatments could be designed to target what a tumor is likely to become, rather than only its current state. As Dr. Marianne Baker, a research information manager at Cancer Research UK, noted, this is early research, but it could help guide the development of treatments that target more of the tumor and keep cancer under control for longer.
The GBM-Space atlas has been made publicly available to assist further research into tumor mechanisms and potential therapeutic interventions. Readers interested in how these findings might relate to specific clinical situations should consult with their qualified medical professionals.